Status: Recruiting
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: EnteromeUpdated: Jan 30, 2026Locations: 12
Eligibility criteria
For inclusion in Cohorts 1 and 4 patients should have relapsed/refractory, biops... [+8]
Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of... [+15]